NASDAQ:RCMR1 RCM Stock Price, Forecast & News

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RCM shares have increased by 4.6% and is now trading at $10.63. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for R1 RCM.

R1 RCM is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for R1 RCM.

R1 RCM Inc (NASDAQ:RCM) posted its quarterly earnings results on Tuesday, May, 5th. The healthcare provider reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by $0.03. The healthcare provider had revenue of $320.50 million for the quarter, compared to analysts' expectations of $318.76 million. R1 RCM had a net margin of 2.44% and a return on equity of 174.42%. R1 RCM's quarterly revenue was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.04) earnings per share. View R1 RCM's earnings history.

6 equities research analysts have issued 12-month target prices for R1 RCM's shares. Their forecasts range from $10.00 to $17.00. On average, they expect R1 RCM's stock price to reach $13.83 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View analysts' price targets for R1 RCM.

Media coverage about RCM stock has been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. R1 RCM earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave headlines about the healthcare provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutR1 RCM.

R1 RCM saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 4,660,000 shares, a decrease of 6.6% from the April 30th total of 4,990,000 shares. Based on an average daily trading volume, of 1,220,000 shares, the days-to-cover ratio is currently 3.8 days. Approximately 4.3% of the shares of the company are sold short. View R1 RCM's Current Options Chain.

Some companies that are related to R1 RCM include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), Alibaba Group (BABA), JD.Com (JD), Baozun (BZUN), Marvell Technology Group (MRVL), Model N (MODN), Baidu (BIDU), BioDelivery Sciences International (BDSI), Perficient (PRFT) and RingCentral (RNG).

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.71%), Wellington Management Group LLP (4.63%), Paradigm Capital Management Inc. NY (3.97%), Sunriver Management LLC (2.91%), State Street Corp (1.98%) and Bank of New York Mellon Corp (1.81%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli, Charles J Ditkoff and Joseph Gerard Flanagan. View institutional ownership trends for R1 RCM.

RCM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Russell Investments Group Ltd., Wellington Management Group LLP, Deutsche Bank AG, Invesco Ltd., BlackRock Inc., and Parametric Portfolio Associates LLC. View insider buying and selling activity for R1 RCM.

RCM stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Sunriver Management LLC, Nuveen Asset Management LLC, Monarch Partners Asset Management LLC, Two Sigma Advisers LP, Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, and Penn Capital Management Co. Inc.. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan. View insider buying and selling activity for R1 RCM.

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RCM stock can currently be purchased for approximately $10.63.

R1 RCM has a market capitalization of $1.22 billion and generates $1.19 billion in revenue each year. The healthcare provider earns $12 million in net income (profit) each year or ($0.08) on an earnings per share basis. R1 RCM employs 22,500 workers across the globe.

The official website for R1 RCM is www.r1rcm.com.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected]